Sign in Subscribe
Health care reform

CorMedix's DefenCath Receives Innovative Technology Designation from Vizient

Strategic Insights

— 2 min read

CorMedix's DefenCath, a biopharmaceutical antimicrobial catheter lock solution (CLS), has gained an Innovative Technology designation from Vizient, the largest healthcare performance improvement company in the country. This prestigious recognition was awarded following the company's exhibit at the Vizient Innovative Technology Exchange in September 2025. DefenCath, the first FDA-approved antimicrobial CLS in the US, has demonstrated a significant reduction in catheter-related bloodstream infections (CRBSIs) in adult patients undergoing hemodialysis via a central venous catheter (CVC). CorMedix is committed to working with Vizient to maintain and expand patient access to DefenCath.

Key Takeaways:

  • DefenCath, a biopharmaceutical antimicrobial catheter lock solution (CLS), has received an Innovative Technology designation from Vizient, the largest healthcare performance improvement company in the country.
  • DefenCath is the first FDA-approved antimicrobial CLS in the US and has demonstrated a significant reduction in catheter-related bloodstream infections (CRBSIs) in adult patients undergoing hemodialysis via a central venous catheter (CVC).
  • CorMedix exhibited DefenCath at the Vizient Innovative Technology Exchange on September 17, 2025, and received the designation following a review by healthcare experts on Vizient client-led councils.
  • Innovative Technology designations are awarded to previously contracted products to signal healthcare providers the impact of these innovations on patient care and business models of healthcare organizations.
  • DefenCath is an FDA-approved antimicrobial CLS for the prevention of CRBSIs in adult patients with kidney failure receiving chronic hemodialysis through a CVC.
  • In the Company's Phase 3 LOCK IT-100 clinical study, DefenCath showed a 71% reduction in the risk of developing a CRBSI and adverse events comparable to control.
  • CorMedix has an ongoing real-world evidence study in over 2,000 patients, with expected interim data around year-end.
  • Joseph Todisco, CEO of CorMedix, commented on the designation: "We are proud to have received this important designation from Vizient. DefenCath represents an innovative infection prevention therapy for patients receiving chronic hemodialysis through a central venous catheter. We look forward to working with Vizient to maintain and expand patient access to our product."
  • Kelly Flaharty, Senior Director Contract Services and Vizient Innovative Technology Program leader, congratulated CorMedix on the achievement: "Our client council deemed DefenCath worthy of this designation for its potential to make a real difference in the healthcare industry."

Statistics:

  • DefenCath has demonstrated a 71% reduction in the risk of developing a CRBSI in the Company's Phase 3 LOCK IT-100 clinical study.
  • CorMedix has an ongoing real-world evidence study in over 2,000 patients, with expected interim data around year-end.
  • Vizient represents a diverse client base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks, and non-acute healthcare providers, with annual purchasing volume of approximately $156 billion.

Sources:

  • GlobeNewswire, "CorMedix Announces that DefenCath Received an Innovative Technology Designation from Vizient" (October 23, 2025)
  • CorMedix, "About DefenCath" (available upon request)
  • Vizient, "Vizient and KLAS Research Offer the 2025 Best in KLAS: Software & Services Awards" (available upon request)
  • SEC filings, CorMedix, Inc. (available upon request)

Read more